Drug Maker Pfizer Adds New Board MemberDrug Maker Pfizer Adds New Board Member
March 5, 2020
Biopharmaceutical firm Pfizer Inc. recently elected Massachusetts Institute of Technology (MIT) Professor of Neuroscience and President Emerita Dr. Susan Hockfield to its Board of Directors, the company announced in a release Wednesday. In addition to her new position, Hockfield will also serve on the board’s Regulatory and Compliance Committee and the Science and Technology Committee.
“We are fortunate to welcome Dr. Susan Hockfield to Pfizer’s Board of Directors,” the company’s chairman and chief executive officer, Albert Bourla, said in a statement. “We continue to infuse our board with scientific expertise in support of our strategic focus on innovation and advancing our pipeline. As a distinguished neuroscientist and highly respected academic leader, Dr. Hockfield will bring tremendous value to the company and our shareholders.”
Dr. Hockfield was the first woman to lead MIT, serving as its sixteenth president from 2004 to 2012, and was also the first life scientist to occupy that position. She currently is a member of the Koch Institute for Integrative Cancer Research at MIT. Prior to her work at MIT, Dr. Hockfield was the William Edward Gilbert Professor of Neurbiology, Dean of the Graduate School of Arts and Sciences from 1998 to 2002 at Yale University. From 2003 to 2004, she was the university’s provost.
The new board member is a member of the American Association for the Advancement of Sciences, the American Academy of Arts and Sciences, and the Society for Neuroscience. Dr. Hockfield earned a B.S. in Biology from the University of Rochester and a Ph.D. in Anatomy and Neuroscience from Georgetown University School of Medicine.
Dr. Albert Gourla became the CEO of Pfizer on Jan. 1, 2019, replacing Ian Read. He previously served as COO and headed up up the firm’s Innovative Health unit. During his tenure at the company, he also established the innovative Health Emerging Markets region and served as group president of the Vaccines, Oncology, and Consumer Healthcare business.
For more news headlines, articles, and equipment reviews, visit our Equipment Zones
More Powder & Bulk Solids articles:
You May Also Like